Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lineagen Applies Affymetrix' GeneChip® Technology to Next-Generation FirstStepDx® Service

Published: Wednesday, March 28, 2012
Last Updated: Wednesday, March 28, 2012
Bookmark and Share
Service for individuals with developmental delay and autism spectrum disorders.

Affymetrix, Inc. and Lineagen, Inc. announced the companies have signed an agreement to incorporate Affymetrix' GeneChip® technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD). The new FirstStepDx offering is anticipated to be available by mid-2012 and will feature a proprietary microarray-based assay incorporating novel genetic markers from recently concluded studies of more than 10,000 individuals. Under the terms of the agreement, Lineagen has exclusive rights to develop a chromosomal microarray assay based on Affymetrix' GeneChip technology platform as part of the Powered by Affymetrix(TM) program. In this program, Affymetrix licenses its technology to companies developing microarray products in a broad range of test applications, including diagnostics. Financial terms of the agreement were not disclosed.

"This agreement further extends our platform with Affymetrix' technology, and we are very excited to incorporate their robust technology into our next-generation FirstStepDx," said Michael Paul, Ph.D., President and CEO of Lineagen. "This next-generation FirstStepDx will assist physicians in the diagnostic evaluation of individuals with DD, ID, or ASD to determine genetic etiology that may influence changes in clinical management and inform appropriate care. The Powered by Affymetrix(TM) program will further ensure we can continue to advance our breakthrough genetic testing by providing market-leading, reproducible, and accurate results."

"We are extremely pleased to formalize a Powered by Affymetrix partnership with an innovative company like Lineagen," said Dara Grantham Wright, VP Global Strategic Marketing for Clinical Applications at Affymetrix. "We are committed to bring our technologies closer to the clinic and to the patients who will benefit most from high quality genetic information."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership
Agreement for diagnostic test development for pathogen detection.
Monday, August 27, 2012
Affymetrix Completes Acquisition of eBioscience Holding Company, Inc.
Acquisition expands Affymetrix’s addressable markets by more than $2.5 billion per year.
Thursday, June 28, 2012
Affymetrix Announces Research Collaboration with MGH
Collaboration and licensing agreement to validate and develop new oncology biomarker tests.
Thursday, June 07, 2012
Affymetrix to Acquire eBioscience
Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments. The transaction is subject to customary closing conditions.
Wednesday, December 14, 2011
Affymetrix to Acquire eBioscience
Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.
Saturday, December 03, 2011
Scientific News
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos